Lab Stakeholders Still Oppose FDA’s Multivariate Assay Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
Laboratories are urging FDA to once again rework, if not abandon, its proposal to actively regulate certain lab-developed tests.